Recognition of risk factors for extended disease and relapse in endometrial carcinoma biopsies, an observational study.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON29070

Enrollment

300

Registered

2012-07-03

Start date

2011-09-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postmenopausal bleeding

Interventions

Immunohistochemical analysis of ER, PR, IMP3, L1CAM, p53, p16, Ki-67, stathmin, PTEN, beta-catenin, ARID1A, MLH1, PMS2, MSH2, MSH6.

Eligibility

Inclusion criteria

Inclusion criteria: Patients with a primary endometrial carcinoma being considerd for operation.

Exclusion criteria

Exclusion criteria: 1. No pre-operative histology; 2. Benign pre-operative histology; 3. No operation because of co-morbidity / wish patient; 4. History of hysterectomy and/or endometrial carcinoma.

Design outcomes

Primary

Measure	Time frame
1. Final pathology; 2. Myometrial invasion; 3. Lymph node involement.	—

Secondary

Measure	Time frame
1. Extended disease; 2. Recurrence; 3. Disease free survival.	—

Contacts

Public ContactN.C.M. Visser

Radboudumc Nijmegen

nicole.visser@radboudumc.nl+31 (0)24 3614314

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)